MTOR and breast cancer: Recently, reduced NAD+/NADH ratios were shown to drive the metastatic progression of MDA-MB-435 and MDA-MB-231 breast cancer xenografts by activating AKT/mTOR and autophagy signaling pathways while increasing the NAD+/NADH ratio inhibited tumor growth62.